Ahmad Tarhini
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Ahmad Tarhini sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Ahmad Tarhini: 6 sponsored US clinical trials, none currently recruiting.
Ahmad Tarhini sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Carcinoma, Non-Small Cell Lung, with 1 trials.
Upper-quartile sponsor footprint
Ahmad Tarhini sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
6 total, page 1 of 1
A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study
NCT02796352
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
NCT01233687
Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer
NCT00958022
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
NCT00471471
Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma
NCT00610857
Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer
NCT00374140
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
Therapeutic Areas
How the Ahmad Tarhini early-phase archive is shaped
6 indexed studies, none listed as recruiting (0% open); 4 completed (67%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Carcinoma, Non-Small Cell Lung (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Ahmad Tarhini: archived-pipeline peers nationwide
Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Ahmad Tarhini sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 archived trials
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Ahmad Tarhini page
6 registered trials is a research-attention snapshot, not an endorsement of Ahmad Tarhini or any single study.
- None of Ahmad Tarhini's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Carcinoma, Non-Small Cell Lung is the condition Ahmad Tarhini studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Carcinoma, Non-Small Cell Lung trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Ahmad Tarhini pipeline card: 6 registered trials from official public datasets.Report a data error.